ARTL
Price
$13.87
Change
+$0.11 (+0.80%)
Updated
Jul 25, 04:56 PM (EDT)
Capitalization
10.38M
12 days until earnings call
CRMD
Price
$11.51
Change
+$0.01 (+0.09%)
Updated
Jul 25, 04:59 PM (EDT)
Capitalization
864.87M
13 days until earnings call
Interact to see
Advertisement

ARTL vs CRMD

Header iconARTL vs CRMD Comparison
Open Charts ARTL vs CRMDBanner chart's image
Artelo Biosciences
Price$13.87
Change+$0.11 (+0.80%)
Volume$100
Capitalization10.38M
CorMedix
Price$11.51
Change+$0.01 (+0.09%)
Volume$16.83K
Capitalization864.87M
ARTL vs CRMD Comparison Chart in %
Loading...
ARTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARTL vs. CRMD commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARTL is a Hold and CRMD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (ARTL: $13.76 vs. CRMD: $11.50)
Brand notoriety: ARTL and CRMD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARTL: 5% vs. CRMD: 132%
Market capitalization -- ARTL: $10.38M vs. CRMD: $864.87M
ARTL [@Biotechnology] is valued at $10.38M. CRMD’s [@Biotechnology] market capitalization is $864.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $309.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARTL’s FA Score shows that 0 FA rating(s) are green whileCRMD’s FA Score has 0 green FA rating(s).

  • ARTL’s FA Score: 0 green, 5 red.
  • CRMD’s FA Score: 0 green, 5 red.
According to our system of comparison, CRMD is a better buy in the long-term than ARTL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARTL’s TA Score shows that 4 TA indicator(s) are bullish while CRMD’s TA Score has 4 bullish TA indicator(s).

  • ARTL’s TA Score: 4 bullish, 5 bearish.
  • CRMD’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ARTL is a better buy in the short-term than CRMD.

Price Growth

ARTL (@Biotechnology) experienced а -12.19% price change this week, while CRMD (@Biotechnology) price change was +3.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.76%. For the same industry, the average monthly price growth was +19.76%, and the average quarterly price growth was +29.65%.

Reported Earning Dates

ARTL is expected to report earnings on Aug 06, 2025.

CRMD is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+8.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRMD($865M) has a higher market cap than ARTL($10.4M). ARTL YTD gains are higher at: 116.352 vs. CRMD (41.975). CRMD has higher annual earnings (EBITDA): 17.7M vs. ARTL (-9.9M). CRMD has more cash in the bank: 77.5M vs. ARTL (746K). ARTL has less debt than CRMD: ARTL (95K) vs CRMD (477K). CRMD has higher revenues than ARTL: CRMD (82.6M) vs ARTL (0).
ARTLCRMDARTL / CRMD
Capitalization10.4M865M1%
EBITDA-9.9M17.7M-56%
Gain YTD116.35241.975277%
P/E RatioN/A46.00-
Revenue082.6M-
Total Cash746K77.5M1%
Total Debt95K477K20%
FUNDAMENTALS RATINGS
ARTL vs CRMD: Fundamental Ratings
ARTL
CRMD
OUTLOOK RATING
1..100
9552
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
10070
SMR RATING
1..100
9945
PRICE GROWTH RATING
1..100
3448
P/E GROWTH RATING
1..100
10056
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARTL's Valuation (70) in the null industry is in the same range as CRMD (76) in the Medical Specialties industry. This means that ARTL’s stock grew similarly to CRMD’s over the last 12 months.

CRMD's Profit vs Risk Rating (70) in the Medical Specialties industry is in the same range as ARTL (100) in the null industry. This means that CRMD’s stock grew similarly to ARTL’s over the last 12 months.

CRMD's SMR Rating (45) in the Medical Specialties industry is somewhat better than the same rating for ARTL (99) in the null industry. This means that CRMD’s stock grew somewhat faster than ARTL’s over the last 12 months.

ARTL's Price Growth Rating (34) in the null industry is in the same range as CRMD (48) in the Medical Specialties industry. This means that ARTL’s stock grew similarly to CRMD’s over the last 12 months.

CRMD's P/E Growth Rating (56) in the Medical Specialties industry is somewhat better than the same rating for ARTL (100) in the null industry. This means that CRMD’s stock grew somewhat faster than ARTL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARTLCRMD
RSI
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 16 days ago
78%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ARTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SBICX10.11N/A
N/A
ClearBridge International Value C
PRJCX40.70N/A
N/A
PGIM Jennison Global Opportunities C
RYLIX104.98N/A
N/A
Rydex Leisure Inv
SVOAX14.90N/A
N/A
SEI US Managed Volatility F (SIMT)
IUEFX29.03-0.24
-0.82%
JPMorgan International Focus R5

ARTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARTL has been loosely correlated with PALI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ARTL jumps, then PALI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARTL
1D Price
Change %
ARTL100%
-6.65%
PALI - ARTL
34%
Loosely correlated
-9.02%
CRMD - ARTL
32%
Poorly correlated
-1.03%
FATE - ARTL
31%
Poorly correlated
-2.34%
LSTA - ARTL
29%
Poorly correlated
+0.38%
CLDI - ARTL
28%
Poorly correlated
+4.42%
More

CRMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRMD has been loosely correlated with MURA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CRMD jumps, then MURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRMD
1D Price
Change %
CRMD100%
-1.03%
MURA - CRMD
38%
Loosely correlated
+0.41%
ARTL - CRMD
33%
Poorly correlated
-6.65%
RLYB - CRMD
32%
Poorly correlated
-0.95%
XLO - CRMD
31%
Poorly correlated
+0.09%
AXON - CRMD
30%
Poorly correlated
+0.57%
More